1 / 17

Genetic disorders of metabolism. Screening methods.

Genetic disorders of metabolism. Screening methods. . Bruno Sopko. Biochemical genetics: Genetic disorders of metabolism. Biochemistry. Genetics. Clinical medicine. Genetic disorders of metabolism . Rare diseases Prevalence < 1:2000. GDM= cca 1/10 of rare diseases

tuyet
Download Presentation

Genetic disorders of metabolism. Screening methods.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Genetic disorders ofmetabolism.Screening methods. Bruno Sopko

  2. Biochemical genetics:Genetic disorders of metabolism Biochemistry Genetics Clinical medicine

  3. Geneticdisordersofmetabolism. Rare diseases Prevalence < 1:2000 • GDM=cca 1/10 of rare diseases • Cca 700-800 nosologic units (>1000 genes) • Total incidence 1:500 • Each GP has, at least, 1-2 patients with GDM • Cca 30% of these diseases are curable (100 diseases well) Rare diseases GDM

  4. Geneticdisordersofmetabolism - overview

  5. Genetic disorders of metabolism– small and large molecule (organelle) disease

  6. Genetic disorders of metabolism – small and large molecule (organelle) disease < 1500 Da • gases, inorganic ions • Aminoacids • organic acids • Saccharides • Polyols • simple lipids • purins, pyrimidins • Vitamins • oligomers: peptids up to cca 5-10 AA, oligosaccharides • cytosol, mitochondrial stroma, blood, urine > 1500 Da • Glycolipids • Sphingolipids • Plasmalogenes • neutral polysaccharides (glycogen) • Mucopolysaccharides (other oligomers: proteins, nucleic acids...) • Usually associated with membranes • Usually not observed in larger amounts in body fluids ( x MS/MS technology)

  7. Genetic disorders of metabolism – small and large molecule (organelle) disease < 1500 Da • Dependent of exogenous intake • manifested (repeated) by acute toxicity, frequently accompanied by encephalopathy/coma • common hepatopathy • Frequent deviations in common biochemical tests-ammonia, ABB, ketone bodies , glycemia, uric acid... • Symptom occurence dependent on specific nutrition part, fasting catabolism • Possibly chronic (low toxicity) • Usually well cured by diet and vitamin supply > 1500 Da • Usually independent on exogenous nutrition supply • Frequently progressive • Possible fetal dysmorphia • Commonly impairment of nervous system and muscles • Organomegalia as theresulting from lysosomal storage diseases • Diet and vitamins do not have any long term effect

  8. Newbornscreeningin the Czech Republic • Newborn (or neonatal) screening is a process of testing newborn babies for increased risk of certain rare diseases, which in case of early detection and early treatment can prevent serious injury to a child. • At the age of 48-72 hours after birth several drops of blood from the heel of the child are sampled on a special paper and sent for analysis to the screening laboratory. In the event that there was no suspicion of the screened disease (negative result), the respective laboratory does not issue a formal statement on normal findings.

  9. Newbornscreeningin the Czech Republic Lysosmal storage disorders Aminoacidopathy, organic acidurias Fatty acid -oxidation disorders Peroxisomal disorders Mitochondrial diseases Glycosylation disorders Others

  10. Newbornscreeningin the Czech republicScanned disorders • EndocrineDisorders • Congenitalhypothyroidism • Congenitaladrenalhyperplasia • Disturbancesofaminoacidmetabolism • Phenylketonuria • Glutaricaciduria, Type I (glutaryl-CoAdehydrogenasedeficiency) • Isovaleryl-CoAdehydrogenasedeficiency (Isovalericacidemia) • Maplesyrup urine disease • Disordersoffattyacidoxidation • Carnitineuptake/transporterdefects • Carnitine-acylcarnitinetranslocasedeficiency • Carnitinepalmitoyltransferase I deficiency (CPT I) • Carnitinepalmitoyltransferase II deficiency (CPT II) • Verylongchain acyl-CoAdehydrogenasedeficiency (VLCADD) • Longchain L-3 hydroxyacyl-CoAdehydrogenasedeficiency (LCHADD) • Medium chain acyl-CoAdehydrogenasedeficiency (MCADD) • Cysticfibrosis • Cysticfibrosis

  11. Newbornscreeningin the Czechrepublic: Probability according to ethnic group

  12. Congenitaladrenalhyperplasia(CAH) • Autosomal recessive • Laboratory diagnosis: 17-hydroxyprogesterone - increased • Treatment – supplementing steroids • Girls – surgical correction

  13. Phenylketonuria (PKU) and Hyperphenylalaninemia (HPA)

  14. Phenylketonuria (PKU) andHyperphenylalaninemia (HPA) PKU HPA

  15. Phenylketonuria (PKU) andHyperphenylalaninemia (HPA) • Autosomal recessive • Laboratory diagnosis: increased phenylalanine, and ratio Phe/Tyr • Treatment – alimentary – decreased intake Phe and supplemented Tyr

  16. Cystic fibrosis (CF) • Autosomalrecessive • Laboratory diagnosis: Three level model IRT/DNA/IRT: • immunoreactivetrypsinogen (IRT) • following DNA analysis • sweat test • Treatment: • Lungs: inhalation mucolytics + breathing physiotherapy in several (idealy 3) short blocks daily. • Well balanced nutrition, high caloric : 130 -150 % RDA, supplementing vitamins soluble in fats, supplementation of NaCl. • Infection control: antibiotics at all acute exacerbation respiratory infection, broad-spectrum antibiotics, with antistaphylococcus effect; when deteced Pseudomonas aeruginosaspecificATB therapy, even withou clinical manifestation. High limit dosages, at least 14 days.

  17. Citations: • http://www.novorozeneckyscreening.cz • Kožich, V. : Úvod do biochemické Genetiky • Jean-Marie Saudubray, Georges van den Berghe, John H. Walter:Inborn Metabolic • Diseases; Diagnosis and Treatment;Fifth Edition, Springer, 2012 • William L. Nyhan, Bruce A. Barshop, Pinar T. Ozand, MD: Atlas of Metabolic Diseases; Second edition, HodderEducation,2005 • Joe T. R. Clarke: A Clinical Guide toInherited MetabolicDiseases;Second Edition, Cambridge University Press, 2004

More Related